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Abstract  
 
Background 
Critically ill children are prone to nosocomial infections, which may lead to adverse outcome. Low 
serum concentrations upon admission to the pediatric intensive care unit (PICU) of the MASP-3 protein 
of the lectin pathway of complement activation have been associated with risk of infection and 
prolonged need for intensive care. We hypothesized that also a low upon-admission concentration of 
collectin-L1 (CL-L1), a novel member of this pathway, is independently associated with these adverse 
outcomes. 
Methods 
We quantified the serum concentrations of CL-L1 in 81 healthy children and in 700 critically ill children 
upon PICU admission.  
Results 
CL-L1 concentrations were significantly lower in the critically ill children as compared with the healthy 
children. However, corrected for baseline characteristics, risk factors and several lectin pathway 
proteins, a higher CL-L1 concentration upon PICU admission was independently associated with an 
increased risk of acquiring a new infection and with a prolonged time to PICU discharge. In contrast, a 
low MASP-3 concentration remained independently associated with these adverse outcomes. 
Conclusion 
A high serum CL-L1 concentration in critically ill children upon PICU admission is associated with an 
increased risk of infection and prolonged need of intensive care, and counteracts the protective effect 
of having a high MASP-3 concentration. 
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Introduction 
 
 
Critically ill children are particularly vulnerable to potentially life-threatening nosocomial infections. 
Indeed, secondary infections of diverse origins have been reported to occur in approximately 30% of 
the patients (1). The innate immune system is an ancient, conserved defense mechanism, which 
provides the immediate response that is of paramount importance for the protection against invading 
pathogens as well as for the repair of tissue damage (2). The complement system, which consists of 
soluble proteins acting as pattern recognition receptors, proenzymes, cell surface complement 
receptors and regulatory proteins, is an essential part of innate immunity (3). The complement system 
is important for fighting infections, for clearing immune complexes and cellular waste and for linking 
innate to adaptive immunity. Insufficient as well as excessive activation of this system can be 
detrimental and thus, health depends on a subtle balance (4). Defects in components of the 
inflammatory complement system have been linked to increased susceptibility to infections in young 
children with associated pathologies (5, 6). Also, depletion of complement factors has been shown to 
be associated with adverse outcome in abdominal sepsis (7, 8). On the other hand, excessive 
inflammation, induced by trauma or infection, has also been linked to worsening of organ function and 
shock (9, 10). 
The complement system is redundant and may be activated in different ways. One way is via the so-
called lectin pathway, which recognizes patterns of foreign carbohydrate structures (e.g. on 
pathogens). This pathway may be initiated by different pattern recognition molecules, including 
mannan-binding lectin (MBL), one of the ficolins (H-, M-, and L-ficolin) and the collectins (11, 12). This 
pathway also exhibits the duality of the system, as both insufficient and excessive activation may be 
detrimental. For example, an increased susceptibility to secondary infections or complications was 
shown with deficiency in MBL or ficolins in children with cancer and in neonates with NEC [6, 13, 14]. In 
contrast, increased levels of these innate immunity proteins, which could possibly be explained by 
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genetic polymorphism, may contribute to exaggerated inflammatory responses as seen in the acute 
respiratory distress syndrome [15, 16]. Overall, data on the lectin pathway of complement activation 
in critically ill children are scarce. 
We previously studied MBL, M- and H-ficolin, and their MBL-associated serine proteases (MASPs) in a 
large group of critically ill children (17). Serum concentrations of these proteins were lower in critically 
ill children upon admission to the pediatric intensive care unit (PICU) as compared with age-matched 
healthy controls, except for higher concentrations of M-ficolin. In particular a low MASP-3 level upon 
admission was independently associated with the risk of acquiring a new infection and with the risk of 
needing prolonged intensive care.  
Within the last 15 years, a novel group of pattern recognition molecules has been discovered, which 
includes collectin-L1 (CL-L1, also named collectin-10) in addition to CL-K1 (also named collectin-11) and 
CL-P1 (12, 18-21). So far, very little is known about the biological function of this class of collectins. CL-
L1 in particular has been shown to activate complement (22). Elevated circulating CL-L1 concentrations 
have been observed in the early phase of acute liver failure and in cirrhosis (23). Also, evaluation of 
CL-L1 as a screening marker for colorectal cancer showed that higher levels of CL-L1 were associated 
with lower odds of colorectal cancer (24).  
As the collectins have been shown to bind to different microorganisms and altered/exposed structures 
in the body (25), this new group of collections may also play a role in inflammatory conditions. In this 
study, we quantified serum concentrations of CL-L1 in children admitted to the pediatric intensive care 
unit (PICU), in comparison with those of healthy children, and explored the potential association with 
baseline characteristics and clinical outcomes of the critically ill children. We focused on the risk of 
acquiring a new infection and prolonged need for intensive care in view of the association we 
previously observed for low MASP-3 levels with these outcomes. We thus hypothesized that low levels 
of CL-L1 upon PICU admission, possibly induced by surgical, traumatic or other stress, are associated 
with a higher risk of acquiring a new infection and with a prolonged need for intensive care. 
 6 
Results 
 
Serum concentrations of CL-L1 in critically ill children and in healthy children 
In propensity-matched cohorts of 81 critically ill and 81 healthy children, serum concentrations of CL-
L1 were significantly lower in the critically ill children as compared with the healthy children (452 (372-
541) ng/ml versus 561 (518-601) ng/ml, (median (IQR)), p<0.0001). The CL-L1 concentration in the 
propensity score-matched critically ill children did not differ from that in the non-matched children 
(466 (379-564) ng/ml, p=0.51). In the total group of critically ill children, the median CL-L1 serum 
concentration upon PICU admission was 466 (378-562) ng/ml. The CL-L1 concentration increased 
gradually during ICU stay to levels comparable with those in the healthy children (Figure 1). 
 
CL-L1 serum concentrations upon PICU admission in relation to baseline characteristics 
CL-L1 serum concentrations did not differ according to age, BMI, or medical history of diabetes or 
malignancy (data not shown). Cardiac surgery patients presented with higher baseline CL-L1 levels than 
patients admitted to the PICU for any other reason (469 (386-567) ng/ml in cardiac patients versus 441 
(351-528) ng/ml in non-cardiac patients, p=0.02). CL-L1 concentrations upon PICU admission weakly 
correlated inversely with severity of illness, as evaluated by modified PRISM score (rho=-0.200, 
p<0.0001), PELOD score (rho=-0.106, p=0.006), or baseline concentrations of glucose (rho=-0.137, 
p=0.0004), lactate (rho=-0.257, p<0.0001), troponin (rho=-0.152, p=0.004) or Heart-type Fatty Acid 
Binding Protein (HFABP, rho=-0.317, p<0.0001). CL-L1 concentrations correlated directly with the 
concentrations of the other lectin pathway proteins (MBL, MASP-1, MASP-2, MASP-3, MAp44, M- and 
H-ficolin (17)) (Table 1), and inversely with CRP (rho=-0.136, p=0.0006). The correlation was particularly 
strong for MASP-1, MASP-3 and MAp44, which are three alternative splice products encoded by the 
same gene, MASP1. 
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Association of CL-L1 serum concentrations upon PICU admission with outcome of critical illness 
In a multivariable logistic regression analysis, correcting for baseline characteristics, risk factors and 
the other lectin pathway proteins, a higher CL-L1 concentration upon PICU admission was 
independently associated with an increased risk of acquiring a new infection (OR 1.241 (1.031-1.494 
95%CI), p= 0.02) (Table 2A). A low MASP-3 concentration upon PICU admission was independently 
associated with a higher risk of infection in this model (OR 0.701 (0.562-0.864 95%CI), p=0.001). This 
confirmed the association we previously observed for MASP-3, with an even lower odds ratio than in 
the model without CL-L1 (OR 0.809 (0.675-0.959 95%CI), p=0.02) (17). The independent associations 
of CL-L1 and MASP-3 with infection were maintained with the addition of the interaction between both 
protein concentrations to the model, with a p-value of 0.06 for the interaction variable (Table 2B). 
In multivariable Cox proportional hazard analysis, correcting for baseline characteristics, risk factors 
and the other lectin pathway proteins, a high CL-L1 concentration tended to be associated with a 
prolonged time to PICU discharge (p=0.05, Table 3A). The hazard ratio of 0.933 (0.867-1.002 95% CI) 
indicated a lower likelihood of earlier alive discharge at any time with a higher CL-L1 concentration 
upon PICU admission. As for risk of infection, this association was in the opposite direction as that for 
MASP-3, showing a higher likelihood of earlier alive discharge at any time with a higher MASP-3 
concentration (hazard ratio of 1.125 (1.046-1.205 95% CI, p=0.001). Again, this association was 
stronger than for the model without CL-L1 that was previously reported (HR 1.088 (1.020-1.157 95%CI), 
p=0.01) (17). Addition of the interaction between both proteins had no major effect, with a p-value of 
0.92 for the interaction variable (Table 3B). 
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Discussion 
 
In a large cohort of critically ill children, serum concentrations of CL-L1 upon PICU admission appeared 
to be lower than in age-, gender- and BMI-matched healthy controls. Corrected for baseline 
characteristics, risk factors and the other lectin pathway proteins, a higher CL-L1 concentration was 
associated with a higher risk of acquiring a new infection and with risk of a prolonged need for intensive 
care. The previously observed association of a low MASP-3 with a higher risk of these adverse 
outcomes was robustly maintained and became even stronger in this model with CL-L1. 
To date, there is only very limited knowledge on the biological function of the pattern recognition 
molecule CL-L1. CL-L1 is encoded by the COLEC10 gene and is primarily expressed in the liver, placenta 
and adrenal glands (18). Initially, CL-L1 was identified as a cytosolic protein but has now been found in 
the circulation, where it complexes with MBL-associated serine proteases (MASPs), the enzymes 
responsible for activation of complement through the lectin pathway (21, 22, 27). In healthy 
individuals, CL-L1 levels appear to be present at near adult levels at birth and show low variation (22). 
The few occurring fluctuations may have reflected periods of microbial challenge. The authors 
suggested that CL-L1 may have an important role during the first year of life, when other elements of 
the immune system are immature. After major surgery, a modest down-regulation of CL-L1 was 
observed that coincided with the CRP response (22). This is in agreement with the acute decrease in 
serum concentrations of CL-L1 that we observed in response to the severe stress of critical illness in 
children and correlated, although weakly, with the rise in CRP. The drop in CL-L1 in the critically ill 
children was more pronounced with increasing severity of illness. 
We performed multivariable analyses to assess whether the upon PICU admission serum concentration 
of CL-L1 is associated with risk of infection and prolonged need of intensive care. We corrected for the 
classical baseline characteristics and risk factors. However, the innate immune system is an extremely 
complex system of intertwined pathways, whose adequate function depends on a very subtle balance. 
An extraordinary redundancy of most of the system components may mask a deficiency or 
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malfunctioning of an individual component. Moreover, several components display context specific 
properties, where they can act as dual function surveillance molecules, suppressing or enhancing 
inflammation, as e.g. shown for the lung collectins (26, 28). Therefore, we also corrected for the other 
lectin pathway proteins for which the concentrations upon PICU admission had been measured (17). 
These analyses revealed independent associations with infection and ICU stay for both CL-L1 and 
MASP-3. Intriguingly, these associations were in the opposite direction, despite both proteins being 
reduced in concentration upon PICU admission and a relatively strong correlation between both 
proteins. For CL-L1 a high concentration was associated with new infection and prolonged PICU stay, 
whereas for MASP-3 a low concentration was predictive for these adverse outcomes. This suggests 
that in the context of a sufficiently high MASP-3 concentration, having a high concentration of CL-L1 
would be detrimental as it counteracts the protective effect of having a high MASP-3. This opposition 
by CL-L1 is further supported by the lower odds ratio for risk of infection and higher hazard ratio for 
time to alive discharge from PICU for MASP-3 when CL-L1 is entered in the model. Our analyses were 
not confounded by correlation between the variables in the model, as multicollinearity was carefully 
excluded. The two-sided nature of circulating CL-L1 in critical illness, being reduced as compared with 
healthy controls but higher concentrations being associated with infection and prolonged PICU stay, is 
intriguing. Unfortunately, lack of knowledge about the biological function of CL-L1 hampers 
speculation about the mechanisms that are involved. Clearly, basic scientific research will be needed 
to unravel the mechanistic processes that may underlie our observations. Also the immediate clinical 
relevance of the present findings is currently unclear. However, the data nicely illustrate the complex 
dualism of the inflammatory cascade, where apparently opposite forces are actually complementary 
and regulated in a subtle balance. This insight may contribute to a future of personalized medicine, 
where (a panel of) biomarkers may guide therapy towards enhancing inflammation (in case of 
infection) or suppressing inflammation (when excessive inflammation threatens organ function). 
A major strength of the present findings is that we studied a large, heterogeneous population of 
(critically ill) children, which is quite unique. Indeed, most often clinical studies in ICU exclude children, 
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as they represent only a small population spread over different developmental stages, and results 
obtained from adult studies are too often extrapolated to children. Nevertheless, a limitation of our 
study is that we only showed associations, with no evidence of causality. Secondly, the measurements 
we performed are primarily of hetero-oligomers between CL-L1 and CL-K1 polypeptide chains, two 
collectins that have most likely evolved from the same ancestral gene by gene duplication (21, 27, 29). 
We have observed that there is a tight correlation between the amount of CL-L1 and CL-K1 in plasma 
but no one has studied in detail whether both molecules can be present separately at different sites in 
the body and whether such proteins appear in plasma at extreme conditions (24, 27, 29, 30).  
 
In conclusion, corrected for baseline characteristics, risk factors and several lectin pathway proteins, a 
high serum CL-L1 concentration upon PICU admission is associated with an increased risk of infection 
and prolonged need of intensive care, and counteracts the protective effect on these outcomes of 
having a high MASP-3 concentration. More pathophysiological research will, however, be needed to 
further elucidate the role of CL-L1 during critical illness and during infection in particular. Nevertheless, 
the present findings yield valuable and unique information, which can incite further exploration in this 
relatively new, though expanding field of research. 
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Materials and methods 
 
Subjects 
This study is a pre-planned analysis of all patients (n=700) included in a randomized controlled study 
on tight glycemic control in the PICU (1). The majority of the children were admitted to the PICU after 
cardiac surgery for congenital heart defects (75%), whereas the others were admitted after 
complicated surgery or trauma, after solid organ transplant surgery, or after neurological, infectious 
or other medical disorders. Critically ill children were allocated upon PICU admission to either 
conventional insulin therapy (n=351, insulin was started only when the blood glucose concentration 
exceeded 215 mg/dl and was tapered down or stopped when glycemia fell below 180 mg/dl), or 
intensive insulin therapy (IIT, n=349, insulin was infused to achieve age-adjusted normal fasting glucose 
levels). Both randomization groups were comparable for baseline characteristics (1). The 
characteristics of the total patient cohort are shown in Table 4. In addition, we included 81 healthy 
children (Table 4), who were scheduled for minor ambulatory surgery. Blood was withdrawn 
preoperatively after catheterization that was required for induction and/or maintenance of 
anesthesia. These children were propensity score-matched with critically ill children (vide infra) to 
study the impact of critical illness. The study was approved by the KU Leuven Institutional Review 
Board (ML2586) and was registered with ClinicalTrials.gov (NCT00214916). The study was performed 
in accordance with the 1964 Declaration of Helsinki and its amendments. Written informed consent 
was obtained from the parents or legal guardians of patients and controls.  
 
Blood sampling and biochemical analyses 
Upon PICU admission, serum was collected and stored at -80°C until analysis. For 29 patients no 
baseline serum sample was available. For 40 patients, 20 per randomization group (with comparable 
baseline characteristics, data not shown), additional serum samples collected on day 2, day 4, day 8 (if 
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the patient was still in ICU on those days) and last day in PICU were used to study the time profile of 
CL-L1 during critical illness. 
C-reactive-protein (CRP) was determined by routine clinical chemistry. Whole arterial blood glucose 
was measured at 1-4 hour intervals during ICU stay using the ABL700 blood gas analyzer (Radiometer 
Medical A/S, Copenhagen, Denmark). CL-L1 concentrations were measured in duplicate using an in-
house time-resolved immune-fluorometric assay (TRIFMA) with a setup similar to conventional 
sandwich immune assays (22). However, we used a new and better characterized preparation of 
recombinant CL-L1, resulting in healthy control levels approximately three times lower than given in 
our original report (22). In brief, capture of the protein with anti-CL-L1 and detection of bound CL-L1 
with biotinylated anti-CL-L1, was followed by incubation with Eu3+-labeled streptavidin. After washing, 
the europium bound in the wells was quantified after addition of enhancement solution to the wells, 
and the fluorescence was read using time-resolved fluorometry. Data were analyzed using the 
WorkOut 2 software (PerkinElmer Life Sciences). In addition to a standard curve, consisting of serial 
dilutions of plasma, three internal control plasma samples (representing a high, medium and low 
concentration of the protein) and a buffer control were included on each microtiter plate. All samples 
were analyzed in duplicate and the analysis was repeated if the coefficient of variation was higher than 
20%. The plate was repeated if the quality controls varied with a CV above 15% as compared with a 
collection of previously measured values. If the concentration of the samples exceeded the highest 
value of the standard curve, the assays were repeated at higher dilution. 
 
Statistical analyses  
Data were analyzed with JMP Pro 11.2.0 (SAS Institute Inc., Cary, NC). Two-sided P-values below 0.05 
were considered significant. Data are presented as mean (95% CI), median (IQR), or proportion 
(percentage), as appropriate. Continuous variables were analyzed with the Wilcoxon test, and 
proportions with the chi-square test. Associations between variables were calculated with Spearman’s 
correlation coefficient. To evaluate the association of CL-L1 serum concentrations upon PICU 
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admission with risk of infection, independent of known risk factors, multivariable logistic regression 
analysis was performed. The classical baseline characteristics and risk factors (age, gender, BMI, 
randomization, CRP, history of malignancy, cardiac surgery, modified pediatric risk of mortality (PRISM) 
score) were considered and in view of the potential context-specificity of disturbances in this system 
(26, 28) also the upon-admission concentrations of the other lectin pathway proteins (measured in 
(17)) were added. In a second step, the interaction between CL-L1 and MASP-3 concentrations was 
tested, in which the addition of the CL-L1 * MASP-3 interaction variable to the model assesses whether 
the effect of CL-L1 on risk of infection is different at different values of MASP-3. To evaluate the 
predictive power for likelihood to early alive discharge from PICU, Cox proportional hazard analysis 
was performed entering the same risk factors, with non-survivors censored beyond the longest staying 
survivor, ensuring the most stringent analysis avoiding competing risk between death and earlier 
discharge (31). We excluded multicollinearity of the variables entered in the models via the collinearity 
diagnostics tool in SPSS version 22.0 (32). 
We used propensity-score matching of the SPSS R-menu (Version R2.10.1, R Foundation for Statistical 
Computing) and IBM SPSS Statistics 19 (SPSS Inc, Chicago, IL) to select demographically comparable 
cohorts of healthy and critically ill children (33, 34). Propensity-scores were estimated via logistic 
regression with age, gender and BMI as continuous covariates. One-to-one nearest neighbor matching 
was performed with use of a caliper of 0.004.  
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Figure legend 
 
Figure 1 : CL-L1 serum concentrations during critical illness 
Time profiles of serum concentrations of CL-L1 are shown for 40 critically ill children, with CL-L1 
concentrations measured upon PICU admission (adm), day 2 (D2), day 4 (D4), day 8 (D8) and last day 
in PICU. Data are expressed as box plots, where the central lines indicate the medians, the boxes the 
interquartile ranges and the whiskers the 10th and 90th percentiles. 
 
 Table 1: Correlation between concentrations of CL-L1 and other lectin pathway proteins upon PICU 
admission 
 rho p 
MBL 0.095 0.01 
MASP-1 0.461 <0.0001 
MASP-2 0.175 <0.0001 
MASP-3 0.564 <0.0001 
MAp-44 0.528 <0.0001 
H-ficolin 0.224 <0.0001 
M-ficolin 0.214 <0.0001 
 
  
Table 2: Multivariable logistic regression analysis for risk of new infection 
 Corrected for baseline 
characteristics, risk factors and 
lectin pathway protein 
concentrations 
Corrected for baseline 
characteristics, risk factors and 
lectin pathway protein 
concentrations and interaction 
 Odds ratio (95% CI) a p Odds ratio (95% CI) a p 
Age (per year added)  0.903 (0.853-0.954) 0.0004 0.907 (0.856-0.958) 0.0007 
Gender (male) 1.088 (0.732-1.618) 0.67 1.120 (0.752-1.670) 0.57 
BMI (per kg/m2 added)  0.992 (0.954-1.028) 0.62 0.994 (0.955-1.030) 0.69 
Randomized intervention (IIT) 0.658 (0.446-0.967) 0.03 0.646 (0.437-0.951) 0.02 
Cardiac surgery 0.240 (0.133-0.427) <0.0001 0.263 (0.145-0.473) <0.0001 
Malignancy 0.210 (0.065-0.606) 0.005 0.209 (0.064-0.606) 0.005 
Modified PRISM-score (per unit added) 1.159 (1.114-1.208) <0.0001 1.154 (1.109-1.203) <0.0001 
CRP (per mg/l added) 1.009 (1.004-1.015) 0.0008 1.009 (1.004-1.015) 0.001 
MBL (per µg/ml added)  1.134 (0.950-1.355) 0.16 1.152 (0.964-1.377) 0.11 
MASP-1 (per µg/ml added)  0.951 (0.881-1.025) 0.19 0.957 (0.886-1.031) 0.25 
MASP-2 (per µg/ml added)  0.959 (0.174-5.246) 0.96 1.017 (0.183-5.670) 0.98 
MASP-3 (per µg/ml added)  0.701 (0.562-0.864) 0.001 0.664 (0.530-0.824) 0.0003 
MAp-44 (per µg/ml added) 1.163 (0.878-1.552) 0.29 1.177 (0.890-1.567) 0.25 
M-ficolin (per µg/ml added)  1.073 (0.961-1.343) 0.38 1.086 (0.965-1.377) 0.37 
H-ficolin (per µg/ml added)  1.019 (0.987-1.053)  0.26 1.022(0.990-1.056)  0.19 
CL-L1 (per 0.1 µg/ml added)  1.241 (1.031-1.494) 0.02 1.223 (1.015-1.475) 0.03 
CL-L1 * MASP-3 interaction    0.06 
 
CI, confidence interval; CL-L1, collectin-L1; CRP, C-reactive protein; IIT, intensive insulin therapy; MAp, 
MBL-associated protein; MASP, MBL-associated serine protease; MBL, mannose-binding lectin; PRISM, 
pediatric risk of mortality. a An odds ratio higher than 1 indicates an increased risk of infection. Hence, 
patients with a higher level of CL-L1 upon PICU admission have a higher risk of acquiring a new infection 
in PICU. 
  
Table 3: Cox proportional hazard analysis for likelihood of early alive discharge from PICU. 
 Corrected for baseline 
characteristics, risk factors and 
lectin pathway protein 
concentrations 
Corrected for baseline 
characteristics, risk factors and 
lectin pathway protein 
concentrations and interaction 
 Odds ratio (95% CI) a p Odds ratio (95% CI) a p 
Age (per year added)  1.039 (1.017-1.062) 0.0006 1.039 (1.017-1.062) 0.0007 
Gender (male) 0.955 (0.811-1.124) 0.57 0.956 (0.811-1.127) 0.58 
BMI (per kg/m2 added)  0.997 (0.971-1.017) 0.79 0.997 (0.971-1.017) 0.79 
Randomized intervention (IIT) 1.200 (1.020-1.411) 0.02 1.199(1.020-1.411) 0.02 
Cardiac surgery 1.891 (1.471-2.451) <0.0001 1.897 (1.465-2.477) <0.0001 
Malignancy 0.981 (0.627-1.479) 0.93 0.983 (0.628-1.484) 0.93 
Modified PRISM-score (per unit added) 0.915 (0.898-0.931) <0.0001 0.915 (0.898-0.931) <0.0001 
CRP (per mg/l added) 0.999 (0.997-1.001) 0.32 0.999 (0.997-1.001) 0.32 
MBL (per µg/ml added)  1.040 (0.961-1.121) 0.32 1.040 (0.961-1.123) 0.32 
MASP-1 (per µg/ml added)  1.005 (0.974-1.036) 0.77 1.005 (0.974-1.036) 0.76 
MASP-2 (per µg/ml added)  0.989 (0.497-1.883) 0.97 0.988 (0.497-1.882) 0.97 
MASP-3 (per µg/ml added)  1.125 (1.046-1.205) 0.001 1.123 (1.040-1.211) 0.003 
MAp-44 (per µg/ml added) 0.968 (0.847-1.097) 0.61 0.968 (0.847-1.098) 0.62 
M-ficolin (per µg/ml added)  1.013 (0.957-1.051) 0.59 1.013 (0.957-1.051) 0.58 
H-ficolin (per µg/ml added)  0.998 (0.986-1.010) 0.77 0.998 (0.986-1.010) 0.79 
CL-L1 (per 0.1 µg/ml added)  0.933 (0.867-1.002) 0.05 0.932 (0.865-1.003) 0.06 
CL-L1 * MASP-3 interaction    0.92 
 
CI, confidence interval; CL-L1, collectin-L1; CRP, C-reactive protein; PICU, pediatric intensive care unit; 
IIT, intensive insulin therapy; MAp, MBL-associated protein; MASP, MBL-associated serine protease; 
MBL, mannose-binding lectin; PRISM, pediatric risk of mortality. a A hazard ratio above 1 indicates a 
higher likelihood of earlier discharge alive from the ICU at any time. Hence, higher upon-admission CL-
L1 levels increase the risk of an extended stay in the PICU. 
 
  
Table 4: Patient characteristics 
 Total patient 
population 
Propensity score 
matched population 
 n=700 Critically ill 
children 
n=81 
Healthy 
children 
n=81 
Baseline characteristics    
   Demography    
       Gender (male) (n, %) 401 (57.3) 53 (65.4) 46 (56.8) 
       Age (years) (median - IQR) 1.3 (0.3-5.0) 3.3 (1.6-4.7) 3.6 (1.6-5.3) 
       BMI (kg/m2) (mean - 95%CI) 15.4 (15.0-15.8) 15.8 (15.3-16.3) 16.2 (15.7-16.6) 
   Medical history    
       Malignancy (n, %) 36 (5.1) 7 (8.6)  
       History of diabetes mellitus (n, %) 6 (0.9) 1 (1.2)  
   Diagnostic category    
       Cardiac surgery for congenital heart defects (n, %) 526 (75.1) 56 (69.1)  
       Complicated surgery or trauma (n, %) 74 (10.6) 10 (12.3)  
       Neurological medical disorders (n, %) 21 (3.0) 4 (4.9)  
       Infectious medical diseases (n, %) 32 (4.6) 5 (6.2)  
       Other medical disorders (n, %) 34 (4.9) 4 (4.9)  
       Solid organ transplants (n, %) 13 (1.9) 2 (2.5)  
   PELOD first 24h (median - IQR) 11 (2-12) 11 (2-12)  
   PRISM a (median – IQR) 10 (7-14) 8 (6-13)  
   CRP admission (mg/l) (median - IQR) 28.3 (15.2-77.8) 38 (22-56)  
   Admission blood glucose (mg/dl b) (median - IQR) 129 (98-176) 132 (112-161)  
   Randomisation to intensive insulin therapy, (n, %) 349 (49.9) 48 (59.3)  
Outcome parameters    
   PICU mortality (n, %) 29 (4.1) 3 (3.7)  
   Days in PICU (median - IQR) 3 (2-7) 2 (2-4)  
   Secondary infection (n, %) 231 (33) 19 (23.5)  
   Peak bilirubin >1.5 mg/dl c (n, %) 140 (20.0) 10 (12.3)  
   Days on mechanical ventilation (median - IQR) 2 (1-5) 1 (1-2)  
   Days on vasoactive drug support (median - IQR) 2 (0-4) 1 (0-2)  
CI, confidence interval; CRP, C-reactive protein; PICU, pediatric intensive care unit; IQR, interquartile 
range; PELOD, Pediatric Logistic Organ Dysfunction; PRISM, Pediatric Risk of Mortality. a Modified 
Pediatric Risk of Mortality score: PRISM score calculated with only the admission value of blood 
glucose, which is unaffected by the study intervention. b To convert glucose to mmol/l, multiply by 
0.05551. c To convert bilirubin to μmol/l, multiply by 17.1. 
 

